200 related articles for article (PubMed ID: 20955776)
1. Citalopram reduces endotoxin-induced fatigue.
Hannestad J; DellaGioia N; Ortiz N; Pittman B; Bhagwagar Z
Brain Behav Immun; 2011 Feb; 25(2):256-9. PubMed ID: 20955776
[TBL] [Abstract][Full Text] [Related]
2. Bupropion pre-treatment of endotoxin-induced depressive symptoms.
DellaGioia N; Devine L; Pittman B; Hannestad J
Brain Behav Immun; 2013 Jul; 31():197-204. PubMed ID: 23064079
[TBL] [Abstract][Full Text] [Related]
3. Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression.
Feighner JP; Overø K
J Clin Psychiatry; 1999 Dec; 60(12):824-30. PubMed ID: 10665628
[TBL] [Abstract][Full Text] [Related]
4. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
Burke WJ; Gergel I; Bose A
J Clin Psychiatry; 2002 Apr; 63(4):331-6. PubMed ID: 12000207
[TBL] [Abstract][Full Text] [Related]
5. Citalopram plus low-dose pipamperone versus citalopram plus placebo in patients with major depressive disorder: an 8-week, double-blind, randomized study on magnitude and timing of clinical response.
Wade AG; Crawford GM; Nemeroff CB; Schatzberg AF; Schlaepfer T; McConnachie A; Haazen L; Buntinx E
Psychol Med; 2011 Oct; 41(10):2089-97. PubMed ID: 21349239
[TBL] [Abstract][Full Text] [Related]
6. Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.
Lenox-Smith AJ; Jiang Q
Int Clin Psychopharmacol; 2008 May; 23(3):113-9. PubMed ID: 18408525
[TBL] [Abstract][Full Text] [Related]
7. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
[TBL] [Abstract][Full Text] [Related]
8. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
9. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
Azorin JM; Llorca PM; Despiegel N; Verpillat P
Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
[TBL] [Abstract][Full Text] [Related]
10. Citalopram in patients with fibromyalgia--a randomized, double-blind, placebo-controlled study.
Anderberg UM; Marteinsdottir I; von Knorring L
Eur J Pain; 2000; 4(1):27-35. PubMed ID: 10833553
[TBL] [Abstract][Full Text] [Related]
11. The validity of the depression rating scales in discriminating between citalopram and placebo in depression recurrence in the maintenance therapy of elderly unipolar patients with major depression.
Bent-Hansen J; Lunde M; Klysner R; Andersen M; Tanghøj P; Solstad K; Bech P
Pharmacopsychiatry; 2003 Nov; 36(6):313-6. PubMed ID: 14663657
[TBL] [Abstract][Full Text] [Related]
12. Escitalopram in major depressive disorder: a multicenter, randomized, double-blind, fixed-dose, parallel trial in a Chinese population.
Mao PX; Tang YL; Jiang F; Shu L; Gu X; Li M; Qian M; Ma C; Mitchell PB; Cai ZJ
Depress Anxiety; 2008; 25(1):46-54. PubMed ID: 17149753
[TBL] [Abstract][Full Text] [Related]
13. Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline.
Stahl SM
Biol Psychiatry; 2000 Nov; 48(9):894-901. PubMed ID: 11074227
[TBL] [Abstract][Full Text] [Related]
14. Escitalopram maintenance treatment for prevention of recurrent depression: a randomized, placebo-controlled trial.
Kornstein SG; Bose A; Li D; Saikali KG; Gandhi C
J Clin Psychiatry; 2006 Nov; 67(11):1767-75. PubMed ID: 17196058
[TBL] [Abstract][Full Text] [Related]
15. A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents.
Wagner KD; Robb AS; Findling RL; Jin J; Gutierrez MM; Heydorn WE
Am J Psychiatry; 2004 Jun; 161(6):1079-83. PubMed ID: 15169696
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
Kennedy SH; Andersen HF; Lam RW
J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
[TBL] [Abstract][Full Text] [Related]
17. Short-term intravenous citalopram augmentation in partial/nonresponders with major depression: a randomized placebo-controlled study.
Altamura AC; Dell'Osso B; Buoli M; Bosi M; Mundo E
Int Clin Psychopharmacol; 2008 Jul; 23(4):198-202. PubMed ID: 18545057
[TBL] [Abstract][Full Text] [Related]
18. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
Bielski RJ; Ventura D; Chang CC
J Clin Psychiatry; 2004 Sep; 65(9):1190-6. PubMed ID: 15367045
[TBL] [Abstract][Full Text] [Related]
19. What is the threshold for symptomatic response and remission for major depressive disorder, panic disorder, social anxiety disorder, and generalized anxiety disorder?
Bandelow B; Baldwin DS; Dolberg OT; Andersen HF; Stein DJ
J Clin Psychiatry; 2006 Sep; 67(9):1428-34. PubMed ID: 17017830
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and tolerability of escitalopram in anxiety disorders: a review].
Pelissolo A
Encephale; 2008 Sep; 34(4):400-8. PubMed ID: 18922243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
